Markets

Endocyte (ECYT) Posts Narrower-than-Expected Loss in Q3

An image of a stock chart
Credit: Shutterstock photo

Endocyte, Inc.ECYT reported a third-quarter 2015 loss of 24 cents per share, narrower than the Zacks Consensus Estimate of a loss of 27 cents per share but wider than the year-ago loss of 14 cents per share.

The company earned collaboration revenues of $33,000 in the reported period compared to $3.9 million in the year-ago period. The year-ago quarter included collaboration revenues from Merck and Company Inc. MRK .

The Quarter in Detail

Research and development (R&D) expenses were $6.6 million, up 16% year over year. The increase reflects expenses related to manufacturing of EC1456 as well as investment in dose escalation trials on EC1456 and EC1169, higher compensation expenses (including non cash stock compensation) which was partially offset by lower etarfolatide-related manufacturing expenses.

General and administrative expenses were down 5.8% to $3.8 million reflecting lower legal and patent fees. This was partially offset by higher compensation expenses (including non cash stock compensation).

Once the dose-escalation studies are done, Endocyte is looking to evaluate EC1456 as a monotherapy as well as combination treatment for non-small cell lung cancer and ovarian cancer.

The company raised its 2015 year-end cash balance outlook to $170 million. Earlier, the company had said that it expects the year-end cash balance to exceed $155 million.

Endocyte carries a Zack Rank #3 (Hold). Some better-ranked stocks in the health care sector are Spectrum Pharmaceuticals, Inc. SPPI and Esperion Therapeutics, Inc. ESPR . Each carries a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

SPECTRUM PHARMA (SPPI): Free Stock Analysis Report

MERCK & CO INC (MRK): Free Stock Analysis Report

ENDOCYTE INC (ECYT): Free Stock Analysis Report

ESPERION THERAP (ESPR): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

ESPR SPPI MRK

Other Topics

Stocks

Latest Markets Videos

Zacks

Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

Learn More